Skip to main content

Table 2 Baseline biomarker results prior to chemotherapy

From: Platelet release of Vascular Endothelial Growth Factor (VEGF) in patients undergoing chemotherapy for breast cancer

Coagulation marker

Advanced breast cancer

Early breast cancer

Control

p ANOVA (Scheffe-showing paired comparisons)

sVEGF μg/ml, geometric mean (CI)[n]

344.0 (270.7-437.2)*† [35]

181.0 (155.9-210.2)* [86]

28.8 (25.3-32.8)† [61]

<0.001

(*<0.001, †<0.001)

pVEGF μg/ml, geometric mean (CI)[n]

22.8 (17.6-29.4)*† [35]

14.2 (12.1-16.6)* [86]

15.1 (12.7-17.9)† [61]

0.004

(*0.01, †0.03)

Platelet count × 109/l, mean (CI) [n]

326.7* (286.9-366.5) [36]

309.6 (293.0-326.2) [87]

278.6 (257.7-299.6)* [45]

0.04

*0.05

Platelet VEGF VEGF μg/ml per platelet × 109

median (range) [n]

1.02*†‡ (0.17-3.53) [35]

0.53* (0.05-2.89) [83]

0.53 ‡(0.007-2.48) [45]

0.05

(*<0.001, †0.008,

‡0.002

  1. Analysis of the difference between groups used Analysis of Variance (ANOVA). Where differences were found, further analysis (between pairs of groups, with respective pairs for each molecule marked with *†‡§ was performed using Scheffe. (95% Confidence interval (CI)). sVEGF = serum VEGF; pVEGF = plasma VEGF